Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
03/11/19Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer – - Seres to receive $20 million and financial support for research activities – - Company to further discuss collaboration during webcast Cowen healthcare conference presentation scheduled for 11:20 a.m. ET today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2019-- Seres Therapeutics, I... 
 Printer Friendly Version
03/06/19Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates
- Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis - - Initiated SER-401 Phase 1b study in metastatic melanoma - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported fourth quarter and full year 2018 financial results and provided an operational update. “This has been a highly eventful period where... 
 Printer Friendly Version
03/05/19Seres Therapeutics to Present at Three Upcoming March Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences: Chardan’s Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7th at 8:10 a.m. ET in New York, NY. Cowen and Company 39th Annual Health Care Conference: a corporate overview will be ... 
 Printer Friendly Version
03/04/19Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 4, 2019-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 6... 
 Printer Friendly Version
02/07/19Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
- Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced certain corporate changes to focus resources on its highest priority, clinical-stage microbiome therapeutic candidates. “We believe that microbiome therapeut... 
 Printer Friendly Version
01/15/19Seres Therapeutics Announces Chief Executive Officer Transition
- Eric Shaff, previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer - - Roger J. Pomerantz, M.D., to continue to serve as Chairman - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roge... 
 Printer Friendly Version
01/03/19Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
– Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 million in milestone payments with Phase 2B study start – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 i... 
 Printer Friendly Version